Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV Epidemic: A Plan for the United States. JAMA. 2019;321(9):844–5. https://doi.org/10.1001/jama.2019.1343.

Article  PubMed  Google Scholar 

The Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS Data 2021. [JC3032E] Published: 29 November 2021. https://www.unaids.org/sites/default/files/media_asset/JC3032_AIDS_Data_book_2021_En.pdf [Accessed 01 June 2022]

Roehr B. FDA approves first drug to prevent HIV infection. BMJ. 2012;345: e4879. https://doi.org/10.1136/bmj.e4879.

Article  PubMed  Google Scholar 

Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. https://doi.org/10.1056/nejmoa1108524.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Baeten JM, Heffron R, Kidoguchi L, Mugo NR, Katabira E, Bukusi EA, et al. Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV-1-serodiscordant couples: a prospective implementation study in Kenya and Uganda. PLoS Med. 2016;13(8): e1002099. https://doi.org/10.1371/journal.pmed.1002099.

Article  PubMed  PubMed Central  Google Scholar 

Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9. https://doi.org/10.1016/s1473-3099(14)70847-3.

Article  PubMed  PubMed Central  Google Scholar 

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99. https://doi.org/10.1056/nejmoa1011205.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34. https://doi.org/10.1056/nejmoa1110711.

CAS  Article  PubMed  Google Scholar 

World Health Organization (WHO). Global data shows increasing PrEP use and widespread adoption of WHO PrEP recommendations: global PrEP network highlight - March 2021: World Health Organization; 2021 Published: 16 March 2021. Available from: https://www.who.int/news-room/feature-stories/detail/global-data-shows-increasing-prep-use-and-widespread-adoption-of-who-prep-recommendations. [Accessed 14 June 2022]

Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396(10246):239–54. https://doi.org/10.1016/s0140-6736(20)31065-5.

CAS  Article  PubMed  Google Scholar 

World Health Organization (WHO). Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Published March 2021. 2021 https://apps.who.int/iris/bitstream/handle/10665/341052/9789240023581-eng.pdf?sequence=1&isAllowed=y [Accessed 01 June 2022].

Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016. https://doi.org/10.1056/nejmoa1506110.

Article  PubMed  PubMed Central  Google Scholar 

Baeten JM, Palanee-Phillips T, Mgodi NM, Mayo AJ, Szydlo DW, Ramjee G, et al. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. Lancet HIV. 2021;8(2):e87–95. https://doi.org/10.1016/s2352-3018(20)30304-0.

Article  PubMed  PubMed Central  Google Scholar 

Nel A, van Niekerk N, Kapiga S, Bekker LG, Gama C, Gill K, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375(22):2133–43. https://doi.org/10.1056/nejmoa1602046.

Nel A, van Niekerk N, Van Baelen B, Malherbe M, Mans W, Carter A, et al. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. Lancet HIV. 2021;8(2):e77–86. https://doi.org/10.1016/s2352-3018(20)30300-3.

Article  PubMed  Google Scholar 

Bekker LG, Pike C, Hillier SL. HIV prevention: better choice for better coverage. J Int AIDS Soc. 2022;25(1): e25872. https://doi.org/10.1002/jia2.25872.

Article  PubMed  PubMed Central  Google Scholar 

•• Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595–608. https://doi.org/10.1056/nejmoa2101016. This pivotal paper showed superiority of CAB-LA to daily oral TDF/FTC in preventing HIV infection among 4566 trangender women and men who have sex with men (MSM) in the HPTN 083 trial. The paper also describes INSTI resistance identified in the individuals who seroconverted in the trial.

•• Marzinke MA, Grinsztejn B, Fogel JM, Piwowar-Manning E, Li M, Weng L, et al. Characterization of HIV infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. J Infect Dis. 2021. https://doi.org/10.1093/infdis/jiab152. A detailed evaluation of the 58 infections that occurred in the HPTN 083 study are presented, including data on delayed HIV diagnosis, emergence of drug resistance, and initiation of antiretroviral therapy.

•• Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779-89.https://doi.org/10.1016/s0140-6736(22)00538-4 .The HPTN 084 randomised, double-blind, active-controlled, superiority trial in 3224 reproductive aged women in seven countries in sub-Saharan Africa showed superiority of CAB-LA in preventing HIV infection compared to TDF/FTC.

•• Eshleman SH, Fogel JM, Piwowar-Manning E, Chau G, Cummings V, Agyei Y, et al. Characterization of human immunodeficiency virus (HIV) infections in women who received injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. J Infect Dis. 2022.https://doi.org/10.1093/infdis/jiab576. In depth data on the 40 infections identified in the HPTN 084 study comparing CAB-LA to TDF/FTC in women are detailed in this paper.

Donnell D, Gao F, Hughes J, Hanscom B, Corey L, Cohen MS, et al. Counterfactual estimation of CAB-LA efficacy against placebo using external trials. Abstract 86. Oral-07. Conference on Retroviruses and Opportunistic Infections; 2022; Virtual. 2022 Feb 12–16.

World Health Organization (WHO). Guidelines on long-acting injectable cabotegravir for HIV prevention. Published July 2022. Available from: https://www.who.int/publications/i/item/9789240054097. Accessed 24 Aug 2022.

•• Landovitz RJ, Li S, Eron JJ, Jr., Grinsztejn B, Dawood H, Liu AY, et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020;7(7):e472-e81. https://doi.org/10.1016/s2352-3018(20)30106-5. Participants at low risk for HIV infection were randomly assigned to CAB-LA at different doses to estimate the time to lower limit of quantitation of CAB between the last injection and up to 76 weeks post-final injection. Cabotegravir could be detected at a median of 43 weeks for men and 67 weeks for women, with longer cabotegravir exposure in individuals with higher body-mass indices.

World Health Organization. HIV drug resistance report 2021. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. https://www.who.int/publications/i/item/9789240038608. 2021. Contract No.: ISBN 978–92–4–003860–8.

Johns BA, Kawasuji T, Weatherhead JG, Taishi T, Temelkoff DP, Yoshida H, et al. Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744). J Med Chem. 2013;56(14):5901–16. https://doi.org/10.1021/jm400645w

Smith SJ, Zhao XZ, Burke TR Jr, Hughes SH. Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology. 2018;15(1):37. https://doi.org/10.1186/s12977-018-0420-7.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Yoshinaga T, Kobayashi M, Seki T, Miki S, Wakasa-Morimoto C, Suyama-Kagitani A, et al. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob Agents Chemother. 2015;59(1):397–406. https://doi.org/10.1128/aac.03909-14.

Article  PubMed  Google Scholar 

Yoshinaga T, Seki T, Miki S, Miyamoto T, Suyama-Kagitani A, Kawauchi-Miki S, et al. Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors. Antiviral Res. 2018;152:1–9. https://doi.org/10.1016/j.antiviral.2018.01.013.

CAS  Article  PubMed  Google Scholar 

• Smith SJ, Zhao XZ, Passos DO, Lyumkis D, Burke TR, Jr., Hughes SH. HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants. Antimicrob Agents Chemother. 2020;64(9). https://doi.org/10.1128/aac.00611-20. A panel of INSTI resistance mutants was developed and tested against current and novel integrase inhibitors to better understand the resistance profile of INSTIs.

• Martin C, Gracias S, Charpentier C, Descamps D, Le Hingrat Q, Plantier JC, et al. HIV-1 non-group M phenotypic susceptibility in vitro to bictegravir and cabotegravir. J Antimicrob Chemother. 2021;76(9):2306-9.https://doi.org/10.1093/jac/dkab196. A large panel of clinical isolates of varying subtypes were evaluated for phenotypic susceptibility to cabotegravir to evaluate the effect of naturally occurring polymorphisms on cabotegravir activity.

Zhang WW, Cheung PK, Oliveira N, Robbins MA, Harrigan PR, Shahid A. Accumulation of multiple mutations in vivo confers cross-resistance to new and existing integrase inhibitors. J Infect Dis. 2018;218(11):1773–6. https://doi.org/10.1093/infdis/jiy428.

Article  PubMed  Google Scholar 

Saladini F, Giannini A, Boccuto A, Dragoni F, Appendino A, Albanesi E, et al. Comparable in vitro activities of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations. Antimicrob Agents Chemother. 2019;64(1). https://doi.org/10.1128/aac.01717-19

Oliveira M, Ibanescu RI, Anstett K, Mesplede T, Routy JP, Robbins MA, et al. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology. 2018;15(1):56. https://doi.org/10.1186/s12977-018-0440-3.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Neogi U, Singh K, Aralaguppe SG, Rogers LC, Njenda DT, Sarafianos SG, et al. Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes. AIDS. 2018;32(4):469–76. https://doi.org/10.1097/qad.0000000000001726.

CAS  Article  PubMed  Google Scholar 

• Cheung PK, Shahid A, Dong W, Lepik KJ, Montaner JSG, Brockman MA, et al. Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study. J Antimicrob Chemother. 2022;77(4):979–88. https://doi.org/10.1093/jac/dkab498. A comprehensive series of recombinant NL4.3 viral constructs with different combinations of integrase seqeunce mutations was created and phenotyped to identify the key mutations that confer high-level resitance to INSTIs including cabotegravir.

Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, Gunthard HF, Paredes R, et al. 2019 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2019;27(3):111–21.

PubMed  PubMed Central  Google Scholar 

Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003;31(1):298–303. https://doi.org/10.1093/nar/gkg100.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Shafer RW. Rationale and uses of a public HIV drug-resistance database. J Infect Dis. 2006;194(Suppl 1):S51–8. https://doi.org/10.1086/505356.

Article  PubMed  Google Scholar 

Andrews CD, Spreen WR, Mohri H, Moss L, Ford S, Gettie A, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science. 2014;343(6175):1151–4. https://doi.org/10.1126/science.1248707.

CAS  Article  PubMed  PubMed Central  Google Scholar 

• Radzio-Basu J, Council O, Cong ME, Ruone S, Newton A, Wei X, et al. Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection. Nature communications. 2019;10(1):2005. https://doi.org/10.1038/s41467-019-10047-w. The emergence of INSTI resistance mutations was demonstrated in macaque studies modeling the risk of receiving CAB-LA in the interval between infection and seroconversion.

Orkin C, Arasteh K, Gorgolas Hernandez-Mora M, Pokrovsky V, Overton ET, Girard PM, et al. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. N Engl J Med. 2020;382(12):1124–35. https://doi.org/10.1056/nejmoa1909512.

CAS  Article  PubMed  Google Scholar 

• Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, et al. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Lancet HIV. 2021;8(4):e185-e96.https://doi.org/10.1016/s2352-3018(20)30340-4. The 96-week results of the FLAIR trial for cabotegravir/rilpivirine treatment are presented in this study.

Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499–510. https://doi.org/10.1016/s0140-6736(17)31917-7.

CAS  Article  PubMed  Google Scholar 

• Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2021;396(10267):1994–2005. https://doi.org/10.1016/s0140-6736(20)32666-0. The 48-week results of the ATLAS-2M trial for cabotegravir/rilpivirine treatment in treatment experienced HIV-1 infected adults in 13 countries demonstrated the efficacy and safety of using cabotegravir and rilpivirine therapeutically with dosing every 2 months.

• Jeffrey JL, St Clair M, Wang P, Wang C, Li Z, Beloor J, et al. Impact of integrase sequences from HIV-1 subtypes A6/A1 on the in vitro potency of Cabotegravir or Rilpivirine. Antimicrob Agents Chemother. 2022;66(3):e0170221. https://doi.org/10.1128/aac.01702-21. The integrase polymorphism L74I was not found to impact cabotegravir susceptibility in vitro in HIV-1 subtype B and A6.

Hu ZX, Cordwell T, Jeffrey JL, Kuritzkes DR. Effect of L74I Polymorphisms on fitness of HIV-1 subtype A6 resistant to Cabotegravir. Poster 506. Conference on Retroviruses and Opportunistic Infections; February 12–16, 2022; Virtual; February 12–16, 2022.

Clement ME, Kofron R, Landovitz RJ. Long-acting injectable cabotegravir for the prevention of HIV infection. Curr Opin HIV AIDS. 2020;15(1):19–26. https://doi.org/10.1097/coh.0000000000000597.

Article  PubMed  PubMed Central  Google Scholar 

Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4(8):e331–40. https://doi.org/10.1016/s2352-3018(17)30068-1.

Article  PubMed  Google Scholar 

Eshleman S, Fogel JM, Halvas EK, Mellors JW, Piwowar-Manning EM, Rinehart AR, et al. CAB-LA PrEP: early detection of HIV infection may reduce InSTI resistance risk. Abstract 95. Conference on Retroviruses and Opportunistic Infections; Virtual, February 12–16, 2022.

Joint United Nations Programme on HIV/AIDS (UNAIDS). Global AIDS Update 2021. Confronting inequalities: lessons for pandemic responses from 40 Years of AIDS. [JC3020E] Available from: https://www.unaids.org/sites/default/files/media_asset/2021-global-aids-update_en.pdf; Accessed 14 June 2022.